Home › Non-Hodgkin Lymphoma › Washington › Seattle
Non-Hodgkin Lymphoma clinical trials in Seattle, WA
16 studies for Non-Hodgkin Lymphoma are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- Swedish Cancer Institute (SCI), Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Swedish Cancer Institute, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecruitingPhase 1
- Fred Hutch Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Fred Hutchinson Cancer Research Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- University of Washington Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecruitingPhase 4
- Swedish Cancer Institute, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecruitingPhase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- Swedish Cancer Institute, Seattle
Non-Hodgkin Lymphoma trials in other cities
- Houston, TX31 studies
- New York City, NY31 studies
- Boston, MA26 studies
- Nashville, TN21 studies
- Philadelphia, PA20 studies
- Baldwin Park, CA19 studies
- Atlanta, GA18 studies
- Chicago, IL18 studies
- Milwaukee, WI18 studies
- Columbus, OH18 studies
- Washington, DC18 studies
- Dallas, TX17 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.